Publications by authors named "T Kaburagi"
Article Synopsis
- Vocal distortion is a key singing technique in genres like rock, metal, and Mongolian music, but its production mechanisms in the larynx are not well understood due to limited research.
- This study utilized high-speed digital imaging to observe and classify the laryngeal dynamics of professional singers, aiming to identify how vocal distortions are produced.
- The findings categorized vocal distortions into "periodic" and "aperiodic" groups, revealing that periodic distortions involve vocal fold vibrations while aperiodic distortions stem from chaotic oscillations, highlighting the complexity of voice production.
Background/aim: Atezolizumab, one of the anti-PD-L1 antibodies, targets PD-L1 expressed on cancer cells and antigen-presenting cells. This immune checkpoint inhibitor is now commonly used in combination with chemotherapy. The objectives of this study were to confirm the treatment outcomes of combined atezolizumab plus chemotherapy, and to identify prognostic factors, with a particular focus on the impact of the site of metastasis in real-world clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- * A patient with a history of Behcet's disease developed acute NBD after receiving neoadjuvant chemotherapy for HER2-positive breast cancer, presenting symptoms like headache and muscle weakness.
- * Following successful steroid treatment for NBD and subsequent surgery for breast cancer, the patient remains cancer-free and without recurrence of NBD two years later, highlighting the need for careful chemotherapy selection in such cases.
Article Synopsis
- Atezolizumab, an anti-PD-L1 antibody, is increasingly used with chemotherapy for treating extensive-stage small cell lung cancer (SCLC), aiming to evaluate its effectiveness and factors influencing long-term outcomes in patients.
- In a study of 95 SCLC patients treated with atezolizumab and chemotherapy in Japan from 2019 to 2023, the median progression-free survival was 6.0 months, and the median overall survival was 15.0 months, with some patients achieving progression-free survival lasting over 2 years.
- The findings indicate that the treatment's efficacy and immune-related side effects are consistent with earlier trials, suggesting that this combination therapy may significantly impact
Transient abnormal myelopoiesis (TAM) occurs in 10% of neonates with Down syndrome (DS). Although most patients show spontaneous resolution of TAM, early death occurs in ∼20% of cases. Therefore, new biomarkers are needed to predict early death and determine therapeutic interventions.
View Article and Find Full Text PDF